Pharmacological Management of Cyclic Vomiting Syndrome (CVS) in a 14-Year-Old

ACUTE / ABORTIVE TREATMENT

1. Anti-migraine Agents (5-HT₁ Agonists — Triptans)

• Must be given during the prodrome or very early in the episode to be effective; ineffective once vomiting is established
• The prodrome (pallor, diaphoresis, nausea) is the optimal window

2. Antiemetics

• Ondansetron — oral or IV; first-line antiemetic in children
• Granisetron (IV)

• Aprepitant — emerging evidence, particularly for refractory episodes

• Prochlorperazine (IV) — shown superior to metoclopramide
• Metoclopramide (IV) — alternative

3. Benzodiazepines

• Lorazepam IV — useful in the acute phase; reduces anxiety (which can perpetuate episodes), provides sedation, and has antiemetic properties
• Helps break the episode cycle

4. IV Fluid Resuscitation

• Correction of dehydration; typically D5 normal saline (D5NS) IV
• Hospitalization indicated for severe dehydration/metabolic derangement

5. Analgesics

• IV opioids may be needed for severe abdominal pain during acute episodes (use cautiously; avoid establishing dependence)
• NSAIDs less effective once vomiting is active

PROPHYLACTIC TREATMENT

1. Tricyclic Antidepressants (TCAs) — First-line Prophylaxis

• Works independently of antidepressant effect (neuromodulatory)
• ECG before initiation (QTc monitoring), especially in adolescents
• Side effects: sedation, dry mouth, constipation, weight gain

2. Beta-Blockers

• Propranolol — 0.5–2 mg/kg/day divided BID-TID; max 10–20 mg TID
• Mechanism: autonomic modulation (CVS has strong autonomic component)
• Monitor for bradycardia, hypotension; contraindicated in asthma

3. Antihistamines / Serotonin Antagonists

• Cyproheptadine — particularly useful in younger children (up to ~8–10 years); less preferred at age 14 but can be tried; 0.25–0.5 mg/kg/day
• 5-HT₂A antagonists (e.g., pizotifen) — conditional recommendation (NASPGHAN 2025)

4. NK-1 Receptor Antagonists (Aprepitant)

• Emerging prophylactic role; conditional recommendation in recent guidelines
• Particularly in adolescents with refractory CVS
• Aprepitant 80–125 mg PO before anticipated triggers or episodically

5. Mitochondrial Supplements (adjunct)

• Coenzyme Q10 (CoQ10) — 5 mg/kg/day (max 200 mg/day)
• L-Carnitine — 50–100 mg/kg/day (max 1 g TID)
• Rationale: mitochondrial dysfunction is implicated in CVS pathogenesis
• Anecdotal/limited evidence but widely used given favorable safety profile

6. Anticonvulsants (reserved for refractory cases — use with caution)

• Topiramate — 1–3 mg/kg/day
• Zonisamide, Levetiracetam — alternative options
• Reserved for failed TCA + beta-blocker trials

7. Psychological / Comorbidity Management

• ~20% of CVS patients have comorbid anxiety/depression; SSRIs (fluoxetine, sertraline) if anxiety/depression is co-existing
• Anticipatory anxiety is a known trigger — treating it can reduce episode frequency
• Mirtazapine or olanzapine: for CVS with chronic nausea comorbidity (Harrison's, 22nd ed.)

Practical Algorithm for a 14-Year-Old

ACUTE EPISODE
├─ Prodrome recognized → Sumatriptan (nasal 5–20 mg or oral 25–50 mg)
│   + Lorazepam (if anxiety/agitation)
│   + Ondansetron PO
└─ Established vomiting/dehydration → Hospital admission
    ├─ IV fluids (D5NS)
    ├─ IV ondansetron (scheduled, not PRN)
    ├─ IV lorazepam
    ├─ IV prochlorperazine (if insufficient response)
    └─ IV opioids (if severe abdominal pain)

PREVENTION (≥3–4 episodes/year)
├─ First-line: Amitriptyline (low-dose, titrate slowly) ± CoQ10/L-carnitine
├─ Alternative first-line: Propranolol
├─ Add: Cyproheptadine (limited in adolescents), Aprepitant
└─ Refractory: Topiramate / Zonisamide (with caution)

Key Points Specific to the Adolescent (14-Year-Old)

1. Screen for cannabis use — cannabinoid hyperemesis syndrome mimics CVS and is managed by cessation, not the above drugs
2. Migraine family history — if present, triptans are the most strongly recommended abortive therapy (NASPGHAN 2025 strong recommendation)
3. ECG before TCA — mandatory due to QTc prolongation risk in adolescents
4. Avoid opioid dependence — limit acute opioid use; opioid dependence is a recognized complication of CVS management
5. Trigger avoidance — sleep deprivation, stress, and dietary triggers (chocolate, cheese, MSG) should be addressed alongside pharmacotherapy

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, p. 217
• Yamada's Textbook of Gastroenterology (7th ed.), pp. 1151–1152
• Washington Manual of Medical Therapeutics, p. 692
• Harrison's Principles of Internal Medicine (22nd ed.), p. 342
• NASPGHAN 2025 Pediatric CVS Guidelines [PMID: 40223700]
• AGA 2024 Clinical Practice Update [PMID: 39023502]
• Falsaperla et al., Systematic Review & Meta-Analysis, J Clin Pharmacol 2024 [PMID: 37867371]